Home > PJ (current issue) > News / News Centre | Search

PJ Online homeThe Pharmaceutical Journal
Vol 273 No 7328 p808
4 December 2004

This article
Reprint   Photocopy

  Acrobat Reader


News summary

Related websites
Contract 2005 (more)


NPA calls again on Government to extend contract exit payments

Ash Soni talks to Rosie Winterton

Ash Soni talks to Rosie Winterton

Ash Soni, chairman of the National Pharmaceutical Association, has called on health minister Rosie Winterton to extend the window for exit payments for pharmacy contractors who dispense fewer than 2,000 items a month.

Speaking at the Triennial Chairman’s Dinner held at the Apothecaries Hall, London, earlier this week, where Ms Winterton was chief guest, Mr Soni reiterated the NPA call that the payment of exit payments should not be limited to the first year of the new contract’s existence. “This exit payment should be made available at the end of the three year period to those pharmacies who attempt to meet the requirements of the new contract but find it unachievable. Minister, we would be grateful to have your support for this proposal.”

In reply, Ms Winterton acknowledged that there are details in the new contract to sort out: “I think that with goodwill and determination on all sides, we can make it happen.”

Both Mr Soni and Ms Winterton welcomed the outcome of the new contract ballot and the opportunity that it could offer pharmacists in developing their roles.

However, Mr Soni pointed out that if pharmacists are to demonstrate their potential it is essential that they have access to the relevant part of the patient record and are able to record their own interventions. “We know that there are sensitivities with this.” He said that the profession is still awaiting a promised consultation on this.

Ms Winterton said that the document on pharmacist access to patient records was nearly complete and that the government hoped to begin consultation on that shortly.

Mr Soni also remarked that he was pleased that the Department of Health is now consulting on the issue of independent prescribing which will offer real benefits to patients. The Journal understands that this consultation is not yet in the public domain.

Back to Top


©The Pharmaceutical Journal